Penumbra, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 09, 2021 at 04:05 pm EDT
Share
Penumbra, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 184.258 million compared to USD 105.109 million a year ago. Operating income was USD 10.312 million compared to operating loss of USD 17.649 million a year ago. Net income was USD 9.231 million compared to net loss of USD 11.960 million a year ago. Basic earnings per share from continuing operations was USD 0.25 compared to basic loss per share from continuing operations of USD 0.34 a year ago. For the half year, sales was USD 353.462 million compared to USD 242.438 million a year ago. Operating income was USD 23.775 million compared to operating loss of USD 17.039 million a year ago. Net income was USD 21.067 million compared to net loss of USD 10.535 million a year ago. Basic earnings per share from continuing operations was USD 0.58 compared to basic loss per share from continuing operations of USD 0.3 a year ago. Diluted earnings per share from continuing operations was USD 0.56 compared to diluted loss per share from continuing operations of USD 0.3 a year ago.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
PENUMBRA, INC. 
